Maryland and Virginia health officials have told providers to resume their use of the Johnson & Johnson COVID-19 vaccine after federal agencies lifted a pause on the vaccine.
The decisions came after the Centers for Disease Control and Prevention and the Food and Drug Administration found the benefits of the one-shot vaccine outweigh its risks.
Earlier this month, the agencies announced an investigation into six cases of an extremely rare blood clot disorder in recipients. One woman who died was a 45-year-old Virginia resident who received the vaccine on March 6. No link has been found and CDC data shows about seven million people in the U.S. have received a dose.
We're making it easier for you to find stories that matter with our new newsletter — The 4Front. Sign up here and get news that is important for you to your inbox.
Virginia told providers that they are free to use the shot immediately.
"This extra scrutiny should instill confidence in the system that is in place to guarantee COVID-19 vaccine safety," a statement from the Virginia Department of Health said.
The Maryland Department of Health says it supports the reintroduction and said providers can resume using available Johnson & Johnson vaccines.
The agency said providers should share information about potential risks, including about the rare blood clots.
The Richmond Times-Dispatch reports that prior to the pause, Virginia had administered 184,000 J&J shots. Maryland has given out over 180,000 single-dose shots.
The chances of getting blood clots while infected with COVID-19 is roughly 20% , which is significantly higher than the risk posed by the vaccine.
“This extra scrutiny should instill confidence in the system that is in place to guarantee COVID-19 vaccine safety,” Dr. Danny Avula, the state’s vaccine coordinator, said in a statement Friday. “As with any vaccine, we encourage individuals to educate themselves on any potential side effects and to weigh that against the possibility of hospitalization or death from COVID-19.”
Avula received a J&J vaccine on April 1.